Format

Send to

Choose Destination
Exp Mol Pathol. 2009 Aug;87(1):83-6. doi: 10.1016/j.yexmp.2009.04.004. Epub 2009 May 3.

Metabolic profiling identifies lung tumor responsiveness to erlotinib.

Author information

1
Department of Chemistry University of Louisville, Louisville, KY 40208, USA.

Abstract

A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.

PMID:
19409891
PMCID:
PMC2729693
DOI:
10.1016/j.yexmp.2009.04.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center